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relationshipAbstract In the present study, a series of novel pyrimidines (1) and their thioethers (2–5) were syn-
thesized. Structures of the synthesized compounds were established by IR, 1H NMR, 13C NMR
mass spectral data and elemental analysis. All the newly synthesized compounds were screened
for their in vitro antibacterial and antifungal activities. Among the compounds tested, few were
found to be most effective antibacterial and antifungal agents. The Structure–activity relationship
studies revealed that thiazolopyrimidine derivatives carrying 3-nitrophenyl (4c) or 4-hydroxyphenyl
(4b) group exhibited highest antibacterial activity, whereas dimethylated adduct carrying 3-nitro-
phenyl (2c) group exhibited highest antifungal activity. The results revealed that the synthesized
compounds may be a potential lead for future drug discovery.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
Open access under CC BY-NC-ND license.1. Introduction
Pyrimidine, being an integral part of DNA and RNA, imparts
diverse pharmacological properties such as effective bacteri-
cide and fungicide.1,2 Certain pyrimidine derivatives are also
known to possess antimalarial,3 antiﬁlarial,4 antibacterial,
antifungal,5,6 anticonvulsant7 and antihistamine8 activities.
Some of the 3,4-dihydropyrimidines (DHPM) have emergedas integral backbones of several calcium channel blockers,
antihypertensive agents, adrenergic and neuropeptide antago-
nist.9 Several natural marine products containing the 3,4-dihy-
dropyrimidine core have been reported in the literature with
interesting biological activities such as the anti-HIV alkaloid
batzelladine B.10,11
Fused pyrimidine derivatives have attracted attention of
numerous researchers over many years, due to their important
biological activities. Preclinical data from literature survey
indicated that the heterocycles in association with the pyrimi-
dine have shown good antimicrobial,12–14 antioxidant,14 anti-
tumour,15 analgesic, anti-inﬂammatory16,17 and antipyretic17
activities. In particular, bezimidazolo-pyrimidine18,19 and
thiazolo-pyrimidine20–23 derivatives were found as potent
antimicrobial agents (Fig. 1).
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Figure 1 Structures of the compounds with good antimicrobial activity.
260 C.M. Bhalgat, B. RameshMotivated by the above mentioned ﬁndings and in contin-
uation of our investigation,24 to discover new potentially active
agents, we have synthesized some new pyrimidines (1) and
their thioethers (2–5). All the newly synthesized compounds
were characterized by spectroscopic techniques and evaluated
for their in vitro antibacterial and antifungal activities.
2. Experimental
Unless otherwise noted, materials were obtained from
commercial suppliers and used without further puriﬁcation.
Melting points were determined by Micro control based melt-
ing point instrument and are uncorrected. All reactions were
monitored by thin-layer chromatography on 0.25 mm silica
gel (60GF-254) plates, using ethyl acetate:butanol:chloroform
in the ratio of [1:2:1] as mobile phase and visualized with
UV light. Column chromatography was performed on silica
gel (200–300 mesh). Infra red (IR) spectra were recorded by
using KBr pellet on a Thermo Nicolate IR-400 FTIR spectro-
photometer, 1H NMR spectra were recorded on Bruker
Avance-400F spectrometer (400 MHz) using tetramethylsilane
as internal standard (chemical shift in d ppm) and LC–MS
with Waters Micromass Q-Tof Micro.
2.1. Chemistry
2.1.1. Synthesis of 4-(substituted)-6-oxo-2-sulphanyl-1,6-
dihydropyrimidine-5-carbonitrile (1)
To a mixture of the selected aryl aldehyde (50 mmol) and thio-
urea in absolute ethanol (50 ml), ethyl cyanoacetate (5.7 g,
50 mmol) and potassium carbonate (6.9 g, 50 mmol) were
added. The reaction mixture was heated under reﬂux until
completion of the reaction, and then neutralized with glacial
acetic acid. The separated solid product was ﬁltered, dried
and crystallized from suitable solvents.
2.1.1.1. 4-(3-Hydroxyphenyl)-6-oxo-2-sulphanyl-1,6-dihydro-
pyrimidine-5-carbonitrile(1a). Reaction time: 8 h; Rf value:
0.53; Yield: 58%; M.p. 229 C; IR, cm–1: 3464 (OH), 3326
(NH), 3005 (Ar-CH), 2939 (Aliphatic CH), 2216 (C„N),
1635 (C‚O), 1509 (C‚N), 1481 (C‚C); 1H NMR (DMSO-
d6) d: 4.38 (s, 1H, NH), 6.82–7.24 (m, 4H, Ar-H), 9.57 (s,
1H, SH), 11.52 (s, 1H, OH); MS, m/z: 246.0 (M+1), 247.0
(M+2).
2.1.1.2. 4-(4-Hydroxyphenyl)-6-oxo-2-sulphanyl-1,6-dihydro-
pyrimidine-5-carbonitrile (1b). Reaction time: 10 h; Rf value:
0.48; Yield: 62%; M.p. >250 C; IR, cm–1: 3598 (OH), 3316(NH), 3083 (Ar-CH), 2836 (Aliphatic CH), 2214 (C„N),
1716 (C‚O), 1635 (C‚N), 1509 (C‚C); 1H NMR (DMSO-
d6) d: 4.82 (s, 1H, NH), 6.74 (d, J= 4.2 Hz, 2H, Ar-H), 7.32
(d, J= 4.2 Hz, 2H, Ar-H), 9.46 (s, 1H, SH), 11.58 (s, 1H,
OH); MS, m/z: 246.0 (M+1).
2.1.1.3. 4-(3-Nitrophenyl)-6-oxo-2-sulphanyl-1,6-dihydropyrim-
idine-5-carbonitrile (1c). Reaction time: 7 h; Rf value: 0.58;
Yield: 67%; M.p. 288 C; IR, cm–1: 3431 (NH), 3037 (Ar-
CH), 2936 (Aliphatic CH), 2216 (C„N), 1636 (C‚O), 1523
(C‚N), 1523 (C‚C), 1352 (C-NO2);
1H NMR (DMSO-d6)
d: 4.28 (s, 1H, NH), 7.75–8.54 (m, 4H, Ar-H), 11.73 (s, 1H,
SH); MS, m/z: 273.1 (M-1).
2.1.1.4. 4-(4-Nitrophenyl)-6-oxo-2-sulphanyl-1,6-dihydropyrim-
idine-5-carbonitrile (1d). Reaction time: 11 h; Rf value: 0.55;
Yield: 54%; M.p. 168 C; IR, cm–1: 3400 (NH), 2953 (Ar-
CH), 2856 (Aliphatic CH), 2222 (C„N), 1704 (C‚O), 1602
(C‚N), 1513 (C‚C), 1348 (C-NO2);
1H NMR (DMSO-d6)
d: 4.93 (s, 1H, NH), 7.95 (d, J= 9.2 Hz, 2H, Ar-H), 8.30 (d,
J= 9.2 Hz, 2H, Ar-H), 11.73 (s, 1H, SH); MS, m/z: 272.9
(M1); Anal. calcd. for C11H6N4O3S: C, 48.17; H, 2.21; N,
20.43. Found: C, 48.06; H, 2.17; N, 20.35.2.1.2. Synthesis of 4-(substituted)-1-methyl-2-
(methylsulphanyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile
(2)
To a solution of the selected 1a–d (20 mmol) in dimethylform-
amide (DMF, 30 ml), methyl iodide (5.68 g, 40 mmol) and
potassium carbonate (5.52 g, 40 mmol) were added. The reac-
tion mixture was stirred at room temperature until completion
of the reaction. The reaction mixture was then diluted with ice
cold water and neutralized with glacial acetic acid. The sepa-
rated solid product was ﬁltered, dried and crystallized from
DMF/water.
2.1.2.1. 4-(3-Hydroxyphenyl)-1-methyl-2-(methylsulphanyl)-6-
oxo-1,6-dihydropyrimidine-5-carbonitrile (2a). Reaction time:
3 h; Rf value: 0.60; Yield: 75%; M.p. 172 C; IR, cm–1: 3366
(OH), 3021 (Ar-CH), 2978 (Aliphatic CH), 2217 (C„N),
1672 (C‚O), 1550 (C‚N), 1414 (C‚C), 1344 (CANAC),
1141 (CASAC); 1H NMR (DMSO-d6) d: 2.72 (s, 3H, S-
CH3), 3.82 (s, 3H, N-CH3), 6.79–7.58 (m, 4H, Ar-H), 9.50 (s,
1H, OH); MS, m/z: 274.0 (M+1).
2.1.2.2. 4-(4-Hydroxyphenyl)-1-methyl-2-(methylsulphanyl)-6-
oxo-1,6-dihydropyrimidine-5-carbonitrile (2b). Reaction time:
5 h; Rf value: 0.58; Yield: 79%; M.p. 222 C; IR, cm–1: 3264
Novel pyrimidines and their thioethers 261(OH), 2937 (Ar-CH), 2865 (Aliphatic CH), 2213 (C„N), 1634
(C‚O), 1600 (C‚N), 1537 (C‚C), 1367 (CANAC), 1165
(CASAC); 1H NMR (DMSO-d6) d: 2.04 (s, 3H, S-CH3), 3.77
(s, 3H, N-CH3), 6.85 (d, J= 8.8 Hz, 2H, Ar-H), 7.46 (d,
J= 8.8 Hz, 2H, Ar-H), 9.31 (s, 1H, OH); MS, m/z: 274.0
(M+1),275.0 (M+2), 276.0 (M+2).
2.1.2.3. 1-Methyl-2-(methylsulphanyl)-4-(3-nitrophenyl)-6-
oxo-1,6-dihydropyrimidine-5-carbonitrile (2c). Reaction time:
4 h; Rf value: 0.63; Yield: 82%; M.p. 195 C; IR, cm–1: 3094
(Ar-CH), 2924 (Aliphatic CH), 2220 (C„N), 1687 (C‚O),
1533 (C‚N), 1486 (C‚C), 1346 (CANAC), 1310 (C-NO2),
1094 (CASAC); 1H NMR (DMSO-d6) d: 2.70 (s, 3H, S-
CH3), 3.50 (s, 3H, N-CH3), 7.87–8.76 (m, 4H, Ar-H); MS,
m/z: 303.0 (M+1), 304.0 (M+2); Anal. calcd. for C13H10N4-
O3S: C, 51.65; H, 3.33; N, 18.53. Found: C, 51.68; H, 3.30;
N, 18.47.
2.1.2.4. 1-Methyl-2-(methylsulphanyl)-4-(4-nitrophenyl)-6-
oxo-1,6-dihydropyrimidine-5-carbonitrile (2d). Reaction time:
5 h; Rf value: 0.61; Yield: 76%; M.p. 181 C; IR, cm–1: 3071
(Ar-CH), 2986 (Aliphatic CH), 2214 (C„N), 1641 (C‚O),
1599 (C‚N), 1521 (C‚C), 1413 (CANAC), 1350 (C-NO2),
1110 (CASAC); 1H NMR (DMSO-d6) d: 2.63 (s, 3H, S-
CH3), 3.47 (s, 3H, N-CH3, 8.19 (d, J= 8.8 Hz, 2H, Ar-H),
8.39 (d, J= 8.8 Hz, 2H, Ar-H); 13C NMR (DMSO-d6) d:
14.2, 27.1, 90.7, 113.6, 123.3, 129.1, 145.3, 148.3, 161.6,
164.6, 167.7; MS, m/z: 303.0 (M+1),304.0 (M+2).
2.1.3. Synthesis of 2-(benzylsulphanyl)-4-(substituted)-6-oxo-
1,6-dihydropyrimidine-5-carbonitrile (3)
To a solution of the selected 1a–d (20 mmol) in DMF (30 ml),
benzyl chloride (2.53 g, 20 mmol) and potassium carbonate
(2.76 g, 20 mmol) were added. The reaction mixture was stirred
at room temperature until completion of the reaction. The
reaction mixture was then diluted with ice cold water and neu-
tralized with glacial acetic acid. The separated solid product
was ﬁltered, dried and crystallized from DMF/water.
2.1.3.1. 2-(Benzylsulphanyl)-4-(3-hydroxyphenyl)-6-oxo-1,6-
dihydropyrimidine-5-carbonitrile (3a). Reaction time: 5 h; Rf
value: 0.81; Yield: 83%; M.p. 166 C; IR, cm–1: 3476 (OH),
3261 (NH), 2944 (Ar-CH), 2841 (Aliphatic CH), 2217
(C„N), 1670 (C‚O), 1595 (C‚N), 1487 (C‚C), 1246
(CANAC), 1126 (CASAC); 1H NMR (DMSO-d6) d: 2.87 (s,
1H, NH), 4.77 (s, 1H, CH2), 6.93–7.55 (m, 9H, Ar-H), 10.56
(s, 1H, OH); MS, m/z: 336.1 (M+1); Anal. calcd. for C18H13-
N3O2S: C, 64.46; H, 3.91; N, 12.53. Found: C, 64.32; H, 3.87;
N, 12.41.
2.1.3.2. 2-(Benzylsulphanyl)-4-(4-hydroxyphenyl)-6-oxo-1,6-
dihydropyrimidine-5-carbonitrile (3b). Reaction time: 6 h; Rf
value: 0.82; Yield: 87%; M.p. 229 C; IR, cm–1: 3474 (OH),
3255 (NH), 2939 (Ar-CH), 2863 (Aliphatic CH), 2217
(C„N), 1670 (C‚O), 1593 (C‚N), 1486 (C‚C), 1246
(CANAC), 1126 (CASAC); 1H NMR (DMSO-d6) d: 2.71 (s,
1H, NH), 4.51 (s, 1H, CH2), 6.76–7.41 (m, 9H, Ar-H), 10.32
(s, 1H, OH); 13C NMR (DMSO-d6) d: 36.2, 91.0, 115.8,
116.9, 127.8, 128.3, 128.8, 129.5, 130.2, 137.3, 158.1, 161.5,
164.0, 166.7; MS, m/z: 336.1 (M+1).2.1.3.3. 2-(Benzylsulphanyl)-4-(3-nitrophenyl)-6-oxo-1,6-dihy-
dropyrimidine-5-carbonitrile (3c). Reaction time: 3 h; Rf value:
0.76; Yield: 46%; M.p. 248 C; IR, cm–1: 3215 (NH), 2989 (Ar-
CH), 2869 (Aliphatic CH), 2221 (C„N), 1661 (C‚O), 1532
(C‚N), 1532 (C‚C), 1346 (C-NO2), 1246 (CANAC), 1114
(CASAC); 1H NMR (DMSO-d6) d: 2.16 (s, 1H, NH), 4.48
(s, 1H, CH2), 7.27–8.68 (m, 9H, Ar-H); MS, m/z: 365.4
(M+1).
2.1.3.4. 2-(Benzylsulphanyl)-4-(4-nitrophenyl)-6-oxo-1,6-dihy-
dropyrimidine-5-carbonitrile (3d). Reaction time: 8 h; Rf value:
0.79; Yield: 80%; M.p. 142 C; IR, cm–1: 3219 (NH), 2981 (Ar-
CH), 2841 (Aliphatic CH), 2213 (C„N), 1635 (C‚O), 1581
(C‚N), 1507 (C‚C), 1285 (C-NO2), 1234 (CANAC), 1115
(CASAC); 1H NMR (DMSO-d6) d: 3.33 (s, 1H, NH), 4.42
(s, 1H, CH2), 7.22–8.37 (m, 9H, Ar-H); MS, m/z: 365.9
(M+1).
2.1.4. Synthesis of 7-(substituted)-5-oxo-2,3-dihydro-5H-
[1,3]thiazolo[3,2-a]pyrimidine-6-carbonitrile (4)
To a solution of the selected 1a–c (20 mmol) in DMF (30 ml),
1,2-dichloroethane (1.98 g, 20 mmol) and potassium carbonate
(2.76 g, 20 mmol) were added. The reaction mixture was stirred
at room temperature until completion of the reaction. The
reaction mixture was then diluted with ice cold water and neu-
tralized with glacial acetic acid. The separated solid product
was ﬁltered, dried and crystallized from DMF/water.
2.1.4.1. 7-(3-Hydroxyphenyl)-5-oxo-2,3-dihydro-5H-[1,3]thiaz-
olo [3,2-a]pyrimidine-6-carbonitrile (4a). Reaction time: 10 h;
Rf value: 0.45; Yield: 75%; M.p. >300 C; IR, cm–1: 3525
(OH), 3176 (Ar-CH), 2913 (Aliphatic CH), 2225 (C„N), 1697
(C‚O), 1634 (C‚N), 1553 (C‚C), 1226 (CANAC), 1135
(CASAC); 1H NMR (DMSO-d6) d: 3.63 (t, J= 6.4 Hz, 2H,
S-CH2), 4.46 (t, J= 6.4 Hz, 2H, N-CH2), 6.97–7.38 (m, 4H,
Ar-H), 9.98 (s, 1H, Ar-OH); 13C NMR (DMSO-d6) d: 25.7,
48.9, 89.7, 114.3, 119.3, 120.7, 130.1, 134.1, 138.7, 150.0,
163.7, 162.2, 169.4; MS, m/z: 272.1 (M+1).
2.1.4.2. 7-(4-Hydroxyphenyl)-5-oxo-2,3-dihydro-5H-[1,3]-
thiazolo[3,2-a]pyrimidine-6-carbonitrile (4b). Reaction time:
12 h; Rf value: 0.48; Yield: 72%; M.p. 287 C; IR, cm–1:
3276 (OH), 3066 (Ar-CH), 2962 (Aliphatic CH), 2215
(C„N), 1645 (C‚O), 1601 (C‚N), 1549 (C‚C), 1280
(CANAC), 1164 (CASAC); 1H NMR (DMSO-d6) d: 3.61 (t,
J= 6.0 Hz, 2H, S-CH2), 4.44 (t, J= 6.0 Hz, 2H, N-CH2),
6.91 (d, J= 7.2 Hz, 2H, CH-C-OH of Ar), 7.85
(d, J= 7.2 Hz, 2H, CH-C-pyrimidine of Ar), 10.37 (s, 1H,
Ar-OH); MS, m/z: 272.2 (M+1); Anal. calcd. for C13H9N3O2-
S: C, 57.55; H, 3.34; N, 15.49. Found: C, 57.53; H, 3.30; N,
15.37.
2.1.4.3. 7-(3-Nitrophenyl)-5-oxo-2,3-dihydro-5H-[1,3]thiazol-
o[3,2-a]pyrimidine-6-carbonitrile (4c). Reaction time: 9 h; Rf
value: 0.51; Yield: 77%; M.p. 209 C; IR, cm–1: 3086 (Ar-
CH), 2928 (Aliphatic CH), 2228 (C„N), 1662 (C‚O), 1612
(C‚N), 1503 (C‚C), 1341 (C-NO2),1265 (CANAC), 1114
(CASAC); 1H NMR (DMSO-d6) d: 3.67 (t, J= 6.4 Hz, 2H,
S-CH2), 4.50 (t, J= 6.4 Hz, 2H, N-CH2), 7.82–8.86 (m, 4H,
Ar-H); MS, m/z: 301.0 (M+1).
262 C.M. Bhalgat, B. Ramesh2.1.5. Synthesis of 2-[(1H-benzimidazol-2-ylmethyl)sulphanyl]-
4-(substituted)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (5)
A solution of the appropriate 1a–c (20 mmol) in DMF (30 mL)
containing triethylamine (0.5 mL) was stirred for 1 h. A solu-
tion of 2-chloromethyl-1H-benzo[d]imidazole (3.33 g,
20 mmol) in DMF was then added portion wise and the reac-
tion mixture was stirred at room temperature until completion
of the reaction. Then the reaction mixture was poured onto
crushed ice with stirring. The separated solid product was ﬁl-
tered, dried and crystallized from DMF/water.
2.1.5.1. 2-[(1H-Benzimidazol-2-ylmethyl)sulphanyl]-4-(3-hyd-
roxyphenyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (5a).
Reaction time: 24 h; Rf value: 0.56; Yield: 86%; M.p.
281 C; IR, cm–1: 3430 (OH), 3289 (NH), 3003 (Ar-CH),
2942 (Aliphatic CH), 2218 (C„N), 1626 (C‚O), 1528
(C‚N), 1456 (C‚C), 1230 (CANAC), 1170 (CASAC); 1H
NMR (DMSO-d6) d: 3.73 (s, 1H, NH of benzimidazole),
4.78 (s, 2H, S-CH2), 6.95–7.57 (m, 4H, Ar-H), 7.95 (s, 1H,
NH of pyrimidine), 9.80 (s, 1H, Ar-OH); 13C NMR (DMSO-
d6) d: 27.6, 92.3, 114.6, 115.3, 116.3, 118.4, 119.4, 122.4,
129.5, 136.6, 137.3, 150.0, 157.2, 163.0, 165.8, 167.1; MS, m/
z: 374.3 (M-1); Anal. calcd. for C19H13N5O2S: C, 60.79; H,
3.49; N, 18.66. Found: C, 60.62; H, 3.42; N, 18.52.
2.1.5.2. 2-[(1H-Benzimidazol-2-ylmethyl)sulphanyl]-4-(4-hyd-
roxyphenyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (5b).
Reaction time: 25 h; Rf value: 0.58; Yield: 83%; M.p.
272 C; IR, cm–1: 3453 (OH), 3317 (NH), 2923 (Ar-CH),
2837 (Aliphatic CH), 2206 (C„N), 1609 (C‚O), 1534
(C‚N), 1469 (C‚C), 1280 (CANAC), 1178 (CASAC); 1H
NMR (DMSO-d6) d: 3.76 (s, 1H, NH of benzimidazole),
4.83 (s, 2H, S-CH2), 6.90 (d, J= 6.8 Hz, 2H, CH-C-OH of
Ar), 7.24 (d, J= 7.2 Hz, 2H, CH-C-N of benzimidazole),
7.58 (d, J= 7.2 Hz, 2H, CH-CH-C-N of benzimidazole),
7.89 (d, J= 6.8 Hz, 2H, CH-C-pyrimidine of Ar), 9.45 (s,
1H, NH of pyrimidine), 10.38 (s, 1H, Ar-OH); MS, m/z:
376.2 (M+1).
2.1.5.3. 2-[(1H-Benzimidazol-2-ylmethyl)sulphanyl]-4-(3-
nitrophenyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile(5c).
Reaction time: 22 h; Rf value: 0.61; Yield: 62%; M.p. 183 C;
IR, cm–1: 3411 (NH), 2924 (Ar-CH), 2856 (Aliphatic CH),
2215 (C„N), 1663 (C‚O), 1529 (C‚N), 1458 (C‚C), 1350
(C-NO2), 1268 (CANAC), 1162 (CASAC);
1H NMR
(DMSO-d6) d: 4.60 (s, 2H, S-CH2), 5.43 (s, 1H, NH of benz-
imidazole), 7.18–8.31 (m, 4H, Ar-H), 8.56 (s, 1H, NH of
pyrimidine); MS, m/z: 405.0 (M+1), 406.1 (M+2), 407.1
(M+3).
2.2. Antimicrobial activity
2.2.1. In vitro antibacterial activity
The antibacterial activity of the synthesized compounds was
determined against Gram-positive bacteria (Bacillus subtilis
and Staphylococcus aureus) and Gram-negative bacteria (Pseu-
domonas aeruginosa and Escherichia coli) in DMF by disc dif-
fusion method using nutrient agar as medium.25 The sterile
medium (Nutrient Agar Medium, 15 ml) in each petri plate
was uniformly smeared with cultures of Gram-positive and
Gram-negative bacteria. Sterile discs of 6 mm diameter wereplaced in the petri plates, to which 100 ll solution of synthe-
sized compounds in DMF at different concentrations such as
250, 500 and 1000 lg/ml (25, 50, 100 lg/disc) was added.
The treatment also included 100 ll of DMF as negative control
and Streptomycin as positive control26 for comparison. The
plates were incubated at 37 ± 2 C for 24–48 h and the zone
of inhibition was determined.
2.2.2. In vitro antifungal activity
All the synthesized compounds were screened for their anti-
fungal activity against Aspergillus niger and Candida albicans
in DMF by the disc diffusion method.25 The sterile medium
(Potato Dextrose Agar Medium, 15 ml) in each petri plate
was uniformly smeared with cultures of fungi. Sterile discs of
6 mm diameter were placed in the petri plates, to which
100 ll solution of synthesized compounds in DMF at different
concentrations such as 250, 500 and 1000 lg/ml (25, 50,
100 lg/disc) was added. The treatment also included 100 ll
of DMF as negative control and amphotericin B as positive
control27,28 for comparison. The plates were incubated at
26 ± 2 C for 48–72 h and the zone of inhibition was
determined.
2.2.3. Antibacterial and antifungal activity (Minimum inhibitory
concentration) by serial dilution method
The minimum inhibitory concentration of the compounds was
determined in Nutrient broth (NB) for bacteria and in Sabou-
rauds dextrose broth (SDB) for fungi by the serial dilution
method.29–31 Seeded broth (broth containing microbial spores)
was prepared in NB from 24 h old bacterial cultures on nutri-
ent agar (Hi-media, India) at 37 ± 1 C, whereas fungal spores
from 24 h to 7 days old Sabourauds agar slant cultures were
suspended in SDB. The bacterial suspension was adjusted with
sterile saline to a concentration of 1 · 104–105 CFU. The
compounds (1–5) were screened for their antibacterial and
antifungal activities in triplicate sets at different concentrations
(1000, 500, 250 and 200 lg/mL). The compounds which were
found to be active in primary screening were further diluted
to obtain 100, 50, and 25 lg/mL concentrations. The tubes
were incubated in BOD incubators at 37 ± 1 C for bacteria
and 28 ± 1 C for fungi. The minimum inhibitory concentra-
tion (MIC) was recorded by visual observation after 24 h
(for bacteria) and 72–96 h (for fungi) of incubation. The lowest
concentration, which show no growth after spot subculture
was considered as MIC for each compound. The highest
dilution showing at least 99% inhibition was taken as mini-
mum inhibitory concentration (MIC). Streptomycin and
Amphotericin B were used as standards for bacterial and fun-
gal study, respectively.3. Results and discussion
3.1. Chemistry
In the present work, the title compounds, 4-substituted-6-oxo-
2-sulphanyl-1,6-dihydropyrimidine-5-carbonitrile (1a–d), were
synthesized by potassium carbonate catalysed three-compo-
nent cyclization of aryl aldehydes, thiourea and ethyl cyanoac-
etate in ethanol. Stirring of selected 1a–d and methyl iodide in
DMF in the presence of potassium carbonate yielded dimethy-
NH
N
O
SHR
NC
1
N
N
O
NC
R
H
S
3
Benzyl chloride
K2CO3
DMF
Stirring
R= 3-OH-C6H4 (a); 4-OH-C6H4 (b); 3-NO2-C6H4 (c); 4-NO2-C6H4 (d)
Scheme 2 Schematic representation of synthesis of compounds 3.
NH
N SHR
NC
O
+
Cl
Cl N
N
NC
O
SR
K2CO3
DMF
Stirring1 4
R= 3-OH-C6H4 (a); 4-OH-C6H4 (b); 3-NO2-C6H4 (c)
Scheme 3 Schematic representation of synthesis of compounds 4.
Novel pyrimidines and their thioethers 263lated adduct, 4-(substituted)-1-methyl-2-(methylsulphanyl)-6-
oxo-1,6-dihydropyrimidine-5-carbonitrile (2a–d) (Scheme 1).
The thioether adduct, 4-(substituted)-1-methyl-2-(benzylsul-
phanyl)-6-oxo-1,6-dihydropyrimidine-5-carbonitrile (3a–d) is
also synthesized by stirring selected 1a–d derivatives and ben-
zyl chloride in the presence of potassium carbonate in DMF
(Scheme 2). Stirring of selected 1a–c and 1,2-dichloroethane
in DMF in the presence of potassium carbonate resulted in
cyclization to give 7-(substituted)-5-oxo-2,3-dihydro-5H-
[1,3]thiazolo[3,2-a]pyrimidine-6-carbonitrile (4a–c) (Scheme 3).
Stirring of selected 1a–c and 2-chloromethyl-1H-benzo[d]imid-
azole in the presence of triethylamine in DMF resulted in
another thioether adduct, 2-[(1H-benzimidazol-2-ylmethyl)sul-
phanyl]-4-(substituted)-6-oxo-1,6-dihydropyrimidine-5-carbo-
nitrile (5a–c) (Scheme 4).
3.2. Spectral elucidation
All the pyrimidine derivatives were synthesized and conﬁrmed
by physical data, IR, 1H NMR and Mass spectral data. Struc-
ture of few compounds was also established by 13C NMR. All
the compounds have shown C„N peak in the range of 2228–
2206 cm1, C‚O peak in the range of 1716–1609 cm1, C‚N
peak in the range of 1635–1509 cm1 and C‚C peak in the
range of 1553–1414 cm1 in IR. The phenolic derivatives have
shown the OH peak in the range of 3598–3264 cm1. The nitro
derivatives have shown C-NO2 peak in the range of 1352–
1285 cm1. The 1a–d compounds have shown peak in the
range of 3431–3316 cm1 for the N–H stretch in IR, which is
absent in 2a–d compounds. The 2a–d, 3a–d, 4a–c and 5a–c
compounds have shown CASAC peak in the range of 1178–
1094 cm1. Compounds, 1a–d, 3a–d and 5a–c have shown
peak in the range of 3431–3215 cm1 for NH.
All the compounds have shown peaks for Ar-H in the range
of d 6.74–8.86 in 1H NMR. All the phenolic derivatives have
shown singlets in the range of d 9.31–11.58 for Ar-OH in 1H
NMR. Additionally, 1H NMR of 1a–d has shown NH and
SH singlets, which are absent in 2a–d compounds. The 2a–d
derivatives have shown singlets in the range of d 3.47–3.82
for N-CH3 and d 2.04–2.72 for S-CH3 in
1H NMR.
The 3a–d derivatives have shown singlets in the range of d
4.42–4.77 for S-CH2 and d 2.16–3.33 for NH of pyrimidine.
The 4a–c derivatives have shown triplets in the range of d
3.61–3.67 for S-CH2 and d 4.44–4.50 for N-CH2 in
1H
NMR. The 5a–c derivatives have shown singlets in the range
of d 4.60–4.83 for S-CH2, d 3.73–5.43 for NH of benzimidazole
and d 7.95–9.45 for NH of pyrimidine. The 1H NMR of 1a–d
has shown SH peak, which is absent in 2a–d, 3a–d, 4a–c and
5a–c compounds.R
O
H
+
NC-CH2-COOCH2CH3
C NH2NH2
S
K2CO3
Et-OH
Reflux
R= 3-OH-C6H4 (a); 4-OH-C6H4 (b); 
Scheme 1 Schematic representation oAll the 13C NMR analysed compounds have shown peaks
in the range of d 89.78–92.36 for C-CN of pyrimidine, d
113.68–118.44 for CN, d 161.52–163.71 for NAC‚N of
pyrimidine, d 162.21–165.80 for C‚O of pyrimidine and d
166.78–169.43 for C-Ar of pyrimidine. N-Methylated deriva-
tive, 2d has shown peak at d 27.16 for N-CH3. The 3b and
5a have shown peaks for CH2 at d 36.25 and d 27.66, respec-
tively. The 4c has shown S-CH2 and N-CH2 peaks at d 25.71
and d 48.93, respectively.
All the synthesized derivatives have shown M+1 peak in
mass spectra except 1c, 1d and 5a compounds, which have
shown M1 peak. The IR, 1H NMR, 13C NMR and Mass
spectral data supported the structure of various synthesized
compounds.
3.3. Antimicrobial activity
The newly synthesized compounds were screened for their anti-
microbial activity against Gram-negative bacteria (Escherichia
coli, Pseudomonas aeruginosa), Gram-positive bacteria (Bacil-
lus subtilis and Staphylococcus aureus) and fungi (Candida albi-
cans and Aspergillus niger). The results of preliminary
antibacterial and antifungal testing of the compounds wereNH
N
O
SHR
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N
N
O
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NC CH3
CH3
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CH3I
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2
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Scheme 4 Schematic representation of synthesis of compounds 5.
264 C.M. Bhalgat, B. Rameshreported as zone of inhibition (Table 1 and Table 2) and Min-
imum inhibitory concentration (Table 3). The results of anti-
bacterial studies revealed that thiazolo-pyrimidines (4a–c)
and benzimidazolo-methyl-sulphanyl-pyrimidine (5a–c) deriv-
atives were showing signiﬁcant antibacterial activity against
all the tested strains. Compounds, 2a and 2b are inactive
against all the species of bacteria, whereas compounds 2c–d,
3a and 3d are inactive against Gram-positive bacteria. All
the other derivatives showed moderate to potent activity
against all the bacterial strains. Amongst the derivatives in 1,
3, 4 and 5 series, the 3-nitrophenyl derivatives exhibited potent
antibacterial activity. As compared to the standard streptomy-
cin, compounds 4c, 4b, 5c and 4a exhibited good activity
against all the tested strains, while compounds 5b, 5a, 1c, 1d,
1b and 3c were moderately active. Compound 4c was found
to be most potent against all the species of bacteria. Com-
pounds carrying thiazolo and benzimidazole rings have shown
best results as compared to the other derivatives and hence
favour the antibacterial activity.
The results of preliminary antifungal testing revealed that
compounds 4a, 4b and 3a are inactive against both species ofTable 1 Antibacterial activity of the compoundsa (1–5).
Compounds E. coli1 P. aeruginosa2
25 lg 50 lg 100 lg 25 lg 50 lg 10
1a 9 10 12 8 10 12
1b 10 13 18 8 10 16
1c 11 15 19 8 12 17
1d 11 14 18 9 10 15
2a – – – – – –
2b – – – – – –
2c 7 10 12 9 10 12
2d 6 9 11 6 8 11
3a 7 7 8 6 8 9
3b 8 9 11 8 10 13
3c 10 14 16 9 14 16
3d 8 10 11 7 9 13
4a 14 17 24 10 15 21
4b 15 19 25 12 17 26
4c 15 22 28 13 16 26
5a 13 14 19 10 13 19
5b 13 16 23 10 13 20
5c 13 20 27 12 16 24
Standard 16 21 29 13 19 31
1 Escheria coli.
2 Pseudomonas aeruginosa.
3 Staphylococcus aureus.
4 Bacillus subtilis.
a Zone of inhibition, standard = streptomycin.fungi. Compounds 2c, 2d and 5c exhibited potent activity
against both the species, while the compounds 2a, 2c, 5a, 5b,
1c, 1d, 1b and 1a exhibited moderate to potent activity. Dime-
thylated adduct (2a–d) and benzimidazole substituted deriva-
tives (5a–c) have shown best results as compared to the other
derivatives.
3.4. Structure–activity relationship (SAR) studies
The structure–activity studies showed that depending on the
nature of the heterocyclic skeleton and its substituent, the
newly synthesized compounds exhibit varying degrees of
microbial inhibition. From the in vitro antibacterial screening
results, it has been found that the pyrimidines carrying thiazol-
o (4a–c) and benzimidazole (5a–c) rings have shown better
activity as compared to the other derivatives. Within the same
series the inhibitory activity depends on the nature of substitu-
ent attached to the benzene ring. The antibacterial screening
indicated that the presence of 3-nitrophenyl and 4-hydroxy-
phenyl substitution as in compounds (4c, 4b, 5c, 5b, 1c, 1b,
3c, 3b, 2c and 2b) increased their inhibitory activities comparedB. subtilis3 S. aureus4
0 lg 25 lg 50 lg 100 lg 25 lg 50 lg 100 lg
10 13 16 – – –
10 14 18 6 9 11
11 15 19 11 12 18
10 13 18 7 9 13
– – – – – –
– – – – – –
– – – – – –
– – – – – –
– – – – – –
9 11 14 – – –
10 12 17 9 11 16
– – – – – –
13 17 22 15 17 20
14 17 24 13 18 24
15 20 28 16 21 27
12 13 19 9 13 15
13 14 18 11 14 18
13 16 24 9 15 20
15 20 32 15 22 29
Table 2 Antifungal activities of compoundsa (1–5).
Compounds C. albicans1 A. niger2
25 lg 50 lg 100 lg 25 lg 50 lg 100 lg
1a 8 12 15 9 12 14
1b 8 12 16 10 13 16
1c 10 13 18 11 13 17
1d 9 12 16 9 12 15
2a 11 13 17 10 15 18
2b 10 14 18 10 15 18
2c 12 17 21 11 16 22
2d 11 15 20 12 17 21
3a – – – – – –
3b 8 10 12 8 10 13
3c 10 11 14 10 11 14
3d 9 10 12 9 11 12
4a – – – – – –
4b – – – – – –
4c 7 9 11 7 9 10
5a 10 14 16 10 12 15
5b 10 14 18 10 14 17
5c 11 16 20 12 15 19
Standard 13 15 23 15 17 26
1 Candida albicans.
2 Aspergillus niger.
a Zone of inhibition, standard = amphotericin-B.
Table 3 Antibacterial and antifungal activity (Minimum Inhibitory
Compounds Minimum Inhibitory Concentration (lg/mL)
Gram-negative bacteria Gram
E. coli1 P. aeruginosa2 B. sub
1a 750 750 1000
1b 500 500 750
1c 250 500 500
1d 500 750 750
2a >1000 >1000 >1000
2b >1000 >1000 >1000
2c 750 750 >1000
2d 1000 1000 >1000
3a >1000 1000 >1000
3b 1000 750 1000
3c 500 500 750
3d 1000 1000 >1000
4a 200 250 250
4b 100 100 200
4c 100 100 100
5a 250 500 500
5b 250 250 250
5c 100 200 100
Standard 1 50 50 50
Standard 2 – – –
Standard 1 = streptomycin; standard 2 = amphotericin-B.
1 Escheria coli.
2 Pseudomonas aeruginosa.
3 Staphylococcus aureus.
4 Bacillus subtilis.
5 Candida albicans.
6 Aspergillus niger.
Novel pyrimidines and their thioethers 265to the other compounds in the same series. Further, SAR
studies revealed that pyrimidine having alkyl or aromatic
substitution on sulphur (2a–d, 3a–d) shows less inhibitory
antibacterial results. The maximum inhibition was observed
in thiazolopyrimidines (4a–c). Also, the synthesized com-
pounds carrying the thiazole ring and 3-nitrophenyl (4c) or
4-hydroxyphenyl (4b) group has shown excellent antibacterial
activity as compared to the other derivatives.
From the results of antifungal testing of the compounds, 1–
5, it has been found that the compounds carrying dimethylated
adduct (2a–d) and benzimidazole substituted derivative (5a–c)
have shown better activity as compared to the other deriva-
tives. Compared to the compounds 1a–d, dimethylated adduct,
2a–d, have shown better antifungal activity. This may be due
to increase in lipophilicity. Better antifungal activity by benz-
imidazole derivatives may be due to the presence of imidazole
moiety in the structure. The in vitro antifungal screening indi-
cated that the presence of 3-nitro substitution to the benzene
ring as in compounds, 2c, 5c, 1c, 3c and 4c, increased their
inhibitory activities compared to the other compounds in the
same series. Dimethylated adduct carrying 3-nitrophenyl (2c)
group has shown excellent antifungal activity as compared to
the other derivatives. Thus, the nature of substituent on the
benzene ring and the heterocyclic skeleton attached to
pyrimidine molecules has a strong inﬂuence on the extent of
antimicrobial activity.Concentration) of the compounds (1–5).
-positive bacteria Fungi
tilis3 S. aureus4 C. albicans5 A. niger6
1000 1000 1000
750 750 750
500 500 250
750 750 500
>1000 500 250
>1000 250 250
>1000 100 100
>1000 200 200
>1000 >1000 >1000
>1000 1000 1000
500 750 750
>1000 1000 1000
250 >1000 >1000
100 >1000 >1000
100 1000 1000
500 500 500
250 250 250
200 200 200
50 – –
– 100 50
266 C.M. Bhalgat, B. Ramesh4. Conclusion
In conclusion, we have described simple and efﬁcient protocol
for the synthesis of pyrimidine derivatives (1) and their thio-
ethers (2–5) with good yields. All the synthesized compounds
(1–5) have been investigated for their in vitro antibacterial
and antifungal activities. In the newly synthesized compounds,
it is clear that the highest antibacterial activity was found in
compounds 4c, 4b, 5c and 4a, whereas highest antifungal activ-
ity was observed in compounds 2c, 2d and 5c. The structure–
activity relationship studies revealed that thiazolopyrimidine
derivatives carrying 3-nitrophenyl (4c) or 4-hydroxyphenyl
(4b) group have shown highest antibacterial activity, whereas
dimethylated adduct carrying 3-nitrophenyl (2c) group on
the benzene ring has shown excellent antifungal activity. To
summarize, we found that the novel class of pyrimidines and
their thioethers has emerged as a valuable lead. Few of the syn-
thesized compounds might be useful as antibacterial and anti-
fungal agents in future. These new pyrimidine derivatives have
proved to be promising candidates for further efﬁcacy
evaluation.
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